Alto Neuroscience Announces Multiple Presentations Made At The Society of Biological Psychiatry Annual Meeting, In Toronto, Canada, Held April 24-26, 2025
Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day
H.C. Wainwright Initiates Alto Neuroscience(ANRO.US) With Buy Rating, Announces Target Price $10
Alto Neuroscience Initiated With a Buy at H.C. Wainwright
Alto Neuroscience +26% ANRO Analyst; IBio IBIO -53% Preclinical Data
HC Wainwright & Co. Initiates Coverage On Alto Neuroscience With Buy Rating, Announces Price Target of $10
Alto Neuroscience Analyst Ratings
JonesTrading Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $18
Buy Rating Reaffirmed for Alto Neuroscience, Inc. Amid Promising Pipeline and Upcoming Data Readouts
William Blair Maintains Alto Neuroscience(ANRO.US) With Buy Rating
Wedbush Downgrades Alto Neuroscience(ANRO.US) to Hold Rating, Cuts Target Price to $4
TD Cowen Maintains Alto Neuroscience(ANRO.US) With Buy Rating
Alto Neuroscience, Inc. (ANRO) Gets a Hold From Wedbush
Analysts Offer Insights on NA Companies: Reddit Inc Class A (RDDT) and Alto Neuroscience, Inc. (ANRO)
Alto Neuroscience Advances Clinical Trials With Strong Financials
ALTO NEUROSCIENCE Earnings Results: $ANRO Reports Quarterly Earnings
Alto Neuroscience | 10-K: FY2024 Annual Report
Express News | Alto Neuroscience FY 2024 GAAP EPS $(2.50) Beats $(2.59) Estimate
Alto Neuroscience 2024 Loss/Shr $2.50 >ANRO
Express News | Alto Neuroscience Inc: Expected to Fund Planned Operations Into 2028